+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07149649

Magnesium Supplementation Added to Standard Chemo-immunotherapy for Advanced Non-small Cell Lung Cancer A Double-Blind Randomized Multicenter Phase IIIII Study

Led by Swiss Cancer Institute · Updated on 2026-10-28

230

Participants Needed

9

Research Sites

221 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer NSCLC can improve treatment outcomes and immune response. This phase IIIII randomized, double-blind, placebo-controlled trial focuses on patients with unresectable stage III or metastatic stage IV NSCLC who are scheduled for first-line chemo-immunotherapy. The study explores the impact of correcting magnesium deficiency, which is common during chemotherapy and may reduce the effectiveness of immune checkpoint inhibitors. Participants are randomly assigned to receive either magnesium supplementation or a placebo, both given as intravenous infusions on chemotherapy days and oral tablets three times daily. The magnesium group receives magnesium aspartate hydrochloride tablets and magnesium sulfate infusions alongside standard platinum-based chemo-immunotherapy every three weeks. The placebo group receives matching placebo tablets and infusions with the same chemo-immunotherapy schedule. Magnesium levels are regularly monitored using plasma and urine samples throughout the study. During the trial, participants will undergo evaluations for progression-free survival, overall survival, response rates, adverse events, quality of life, and immune-related biomarkers. The study includes safety monitoring and quality control measures such as electronic data capture and source data verification. Follow-up may extend up to 10 years to assess long-term outcomes. The trial aims to determine if magnesium supplementation can safely enhance treatment effectiveness and patient well-being in advanced NSCLC.

CONDITIONS

Brief Title

Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

Research Team

G

Gisela Müller, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here